Shan Chen

Title: The Innovative Contributions of Shan Chen in Pharmaceutical Technology

Introduction

Shan Chen is a notable inventor based in Hebei, China, recognized for his significant contributions to the field of pharmaceutical technology. His work primarily focuses on innovative treatments for various types of lymphoma, showcasing his dedication to advancing medical science.

Latest Patents

Shan Chen holds a patent for the "Use of mitoxantrone liposome for treating non-Hodgkin's lymphoma." This patent discloses a liposomal pharmaceutical preparation of mitoxantrone designed for the treatment of lymphoma, specifically targeting non-Hodgkin's lymphoma. The invention emphasizes the use of mitoxantrone liposomes as a single anti-tumor therapeutic agent, without the need for combination with other anti-tumor agents. This innovative approach aims to provide effective treatment options for patients suffering from aggressive forms of lymphoma, including relapsed or refractory diffuse large B-cell lymphoma and peripheral T-cell lymphoma.

Career Highlights

Shan Chen is associated with Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., where he applies his expertise in pharmaceutical development. His work at this company has been instrumental in advancing therapeutic options for cancer treatment, particularly in the realm of lymphoma.

Collaborations

Throughout his career, Shan Chen has collaborated with esteemed colleagues such as Chunlei Li and Yueying Peng. These collaborations have fostered a productive environment for innovation and research, contributing to the development of effective pharmaceutical solutions.

Conclusion

Shan Chen's innovative work in the field of pharmaceutical technology, particularly his patent for mitoxantrone liposomes, highlights his commitment to improving cancer treatment. His contributions are paving the way for more effective therapies for patients with non-Hodgkin's lymphoma.